|
ИСТИНА |
Войти в систему Регистрация |
ФНКЦ РР |
||
Comparative evaluation of effectiveness of neoadjuvant chemoimmunotherapy (nPCIT) for non-small cell lung cancer (NSCLC)статья
Статья опубликована в высокорейтинговом журнале
Статья опубликована в журнале из списка Web of Science и/или ScopusДата последнего поиска статьи во внешних источниках: 20 июня 2024 г.
- Авторы: Lazutin Yuri, Pyltsin Sergey P., Turkin Igor N., Vladimirova Liubov Yu, Ayrapetova Tamara G., Chubaryan Anna V., Leyman Igor A., Anistratov Pavel A., Stateshny Oleg N., Shogenov A.S., Gappoeva M.A., Afaunov M., Beleckiy S.G., Isaeva Rukiyat
- Журнал: Journal of Clinical Oncology
- Том: 36
- Номер: 15_suppl
- Год издания: 2018
- Издательство: American Society of Clinical Oncology
- Местоположение издательства: United States
- Первая страница: 8534
- Последняя страница: 8534
- DOI: 10.1200/jco.2018.36.15_suppl.8534
- Аннотация: Background: The purpose of the study was to compare the results of neoadjuvant polychemoimmunotherapy (nPCIT) and conventional neoadjuvant polychemotherapy (nPCT) in patients with NSCLC. Methods: 64 pts with NSCLC were divided into 2 groups: main group – 32 pts, 2 nPCIT cycles (cisplatin 80 mg/m2 on day 1, gemcitabine 1200 mg/m2 on days 1 and 8 with i.v. infusions of the recombinant hybrid protein of tumor necrosis factor-alpha-thymosin-alpha1 100 000 IU on days 0, 3 and 6); control group – 32 pts, nPCT with the same cytostatics. Central cancer in 17(53.1%) pts of the main group (cT1NX-6.2%, cT2NX-37.5%, cT3NX-3.1%) and 20 (62.5%) (cT1NX-9.4%, cT2NX-40.6%) controls, peripheral cancer in 15(46.9%) (cT2b NX-9.4%, cT3> 7 NX-21.8%, cT3NX-18.7%, cT4NX-3.1%) and 12(37.5%) (cT2b NX-12.5%, cT3NX-34.3%, cT4NX-3.1%), respectively. Squamous cell carcinoma in 17(53.2%) and 14(43.8%), adenocarcinoma in 7(21.8%) and 5(15.6%), non-small cell carcinoma in 8(25%) and 13(40.6%) pts, respectively. Results: CR in 3 (9.4%) and 2 (6.2%), PR - 14 (43.7%) and 13 (40.6%), SD - 13 (40.6%) and 14 (43.7%), PD - 2 (6.2%) and 3 (9.4%). Objective overall response rate was 53.1% in nPCIT vs 46.8% in nPCT, CR+PR+SD was 93.7% and 90.6%, respectively. 29 (90.6%) pts in each group received surgery. Extended lobectomy/bilobectomy in 14 (48.2%) pts in each group, extended pneumonectomy in 7 (24.1%) in nPCIT and 8 (27.5%) in nPCT. N2 disease in 10 (34.5%) and 13 (44.8%) pts, respectively. Post-surgical restaging: st. 0 – 10.3% vs 6.9%, st. I - 34.5% vs 31%, st. II - 20.7% vs 17.2%, st. IIIА - 34.5% vs 44.7%. Median survival in the main group - not reached, in controls – 23 months. OS was studied in pts with st. 0-II and st. IIIAN2 NSCLC; 3-year OS in early stages was 72% in the main group vs 49% in controls (p = 0.0735). Conclusions: The direct results were similar in nPCIT and nPCT, but 2-year EFS was 72% and 44%, respectively, with a tendency to improvement (p = 0.05421). 2-year OS in pts with st. IIIAN2 NSCLC improved to 55% in the main group vs 32% in controls (p = 0.031777).
- Добавил в систему: Владимирова Любовь Юрьевна